Explore the latest CAR-T cell therapy reports for multiple myeloma treatment in China. This section provides key clinical trial data, long-term follow-up results, safety profiles, real-world outcomes, and expert commentary on leading MM CAR-T products in China. Designed for international patients and healthcare professionals, it offers clear, reliable insights into China’s rapid progress in CAR-T therapy for multiple myeloma.
A patient with ultra–high-risk multiple myeloma achieved deep and durable remission after ASCT combined with BCMA CAR-T therapy, maintaining sCR with MRD negativity for more than 18 months, highlighting a promising strategy for overcoming high-risk disease.
This real-world case highlights Eque-cel (Fucaso), a fully human BCMA-targeted CAR-T therapy, achieving deep and durable remission in a heavily pretreated multiple myeloma patient following two transplant relapses.
Tim is a multiple myleoma patients from New Zealand.
Fucaso (Equecabtagene Autoleucel) is an innovative CAR-T cell therapy for multiple myeloma. Mrs. Thanyaphat from Thailand has been diagnosed with multiple myeloma, however, she ran out of option at home,
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.